Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

elopment; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

JULY 31, APRIL 30,

2008 2008

Unaudited

ASSETS

CURRENT ASSETS:

Cash and cash equivalents $9,963,000 $15,130,000

Trade and other receivables 2,099,000 605,000

Government contract receivables 1,794,000 -

Inventories, net 4,628,000 2,900,000

Prepaid expenses and other current assets 1,198,000 1,208,000


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... TECHNOLOGY: GLOBAL MARKETS , the global market for digital ... in 2013. This is estimated to grow to $490 ... rate (CAGR) of 28.6%. , New digital PCR technology ... within the broader PCR field. The opportunities presented by ...
(Date:7/11/2014)... -- Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
(Date:7/10/2014)... Mass. (PRWEB) July 10, 2014 Terascala, ... today announced that Alan Swahn, a former vice president ... executive team as vice president of marketing. Terascala’s software ... Dell and NetApp create the highest performance and most ... been appointed to guide Terascala’s channel expansion and broaden ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... River Systems announces,the successful development and operation of ... the development of its Monarch250(TM) proton,therapy system. This ... that cyclotrons at this high field strength can ... increasing the operating,magnetic field, Still River Systems is ...
... May 21 Prime Therapeutics (Prime), a,thought ... that it has,received accreditation from the National ... Verified Internet Pharmacy Practice,Sites(TM) (VIPPS(R)) Program., ... by NABP in response to,consumers, concerns regarding ...
... Aton Pharma, Inc., a global,specialty pharmaceutical company, ... distribution agreement with PharmaLink Asia Pacific Pte. Ltd.,to ... in Asia and,Australia., "This partnership marks an ... to expand access to our medically essential portfolio ...
Cached Biology Technology:Still River Systems Announces Operation of the World's Highest Magnetic Field Cyclotron 2Prime Therapeutics Receives VIPPS Accreditation 2Aton Pharma Announces Distribution Partnership in the Asia Pacific Region 2
(Date:7/11/2014)... hippocampus, the marginal division of the striatum is ... the impact degree of substance P in the ... Yan Yu and his team, College of Biophotonics, ... staining, that substance P receptor, neurokinin 1 was ... division of normal rats. Unilateral or bilateral injection ...
(Date:7/11/2014)... that let nerve cells send out electrical signals, Johns ... tactic that may offer a new way to protect ... responsible way. , Their findingthat naturally occurring insect ... for a closely related onesuggests that insecticides can be ... like bees. A summary of the research, led by ...
(Date:7/10/2014)... 27, 2014  Pomerantz LLP has filed a ... or the "Company")(NYSE-MKT: PVCT) and certain of its ... District Court, Middle District of Tennessee ... a class consisting of all persons or entities ... December 17, 2013 and May 22, 2014, both ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... Ore. The northern spotted owl, a threatened species ... long run from active management of the forest lands ... to stand-replacing fire, researchers conclude in a recent study. ... thinning, or other fuel reduction activities in areas with ...
... gas could become an important source of renewable energy, ... Researchers at both campuses are raising colonies of ... turn electrical energy into pure methane the key ... create large microbial factories that will transform clean electricity ...
... sciences have become especially data-intensive. As researchers rely ... than observations to collect data, discovering, integrating and ... to researchers, ability to address complex questions about ... in it. On March 29, 2012, President ...
Cached Biology News:Active forest management to reduce fire could help protect northern spotted owl 2Stanford-Penn State scientists use microbes to make 'clean' methane 2Stanford-Penn State scientists use microbes to make 'clean' methane 3Stanford-Penn State scientists use microbes to make 'clean' methane 4DataONE answers the call for new tools to study the Earth in this era of Big Data science 2
Multidrop Micro high speed 1 l bulk reagent dispenser rapidly, precisely and accurately dispenses microvolumes of 1-50 l into 384- and 96-well microplates....
...
...
Buckets for tube holder inserts...
Biology Products: